Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: A new pleiotropic effect?

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 839-842

  Athyros, Vasilios G ^a   Tziomalos, Konstantinos ^a   Florentin, Matilda ^b   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Loading; Medical treatment; Percutaneous coronary intervention; Revascularization; Slow reflow phenomenon; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NO-REFLOW PHENOMENON;

EID: 77949537780     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003634338     Document Type: Note

References (29)

1. Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-1278
2. Pasceri V, Patti G, Nusca A et al.; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678
3. Patti G, Chello M, Pasceri V et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy. J Am Coll Cardiol 2006;48:1560-1566
4. Yun KH, Jeong MH, Oh SK et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137:246-251
5. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-565
6. Kinlay S, Schwartz GG, Olsson AG et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of ator-vastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110:386-391
7. Gibson CM, Pride YB, Hochberg CP, et al.; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009;54:2290-2295
8. Cannon CP, Braunwald E, McCabe CH et al.; the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
9. Athyros VG, Kakafika AI, Karagiannis A, et al. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008;200:1-12
10. Athyros VG, Kakafika AI, Tziomalos K et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009;15:479-489
11. Piana RN, Paik GY, Moscucci M et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89:2514-2518
12. Morishima I, Sone T, Okumura K et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209
13. Morishima I, Sone T, Mokuno S et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myo-cardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995;130:239-243
14. Hong SN, Ahn Y, Hwang SH et al. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2007;100:631-634
15. Jia XW, Fu XH, Zhang J et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J (Engl) 2009;122:659-664
16. Paraskevas KI, Athyros VG, Briana DD et al. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 2007;8:942-951
17. Iwakura K, Ito H, Kawano S et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534-539
18. Pasceri V, Patti G, Di Sciascio G. Prevention of myocardial damage during coronary intervention. Cardiovasc Hematol Disord Drug Targets 2006;6:77-83
19. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulatory. Nat Med 2000;6:1399-1402
20. Ridker PM, Cannon CP, Morrow D, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-ITTIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28
21. Fonarow GC, Wright RS, Spencer FA et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005;96:611-616
22. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540-556
23. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96(5A):54F-60F
24. Ray KK, Cannon CP. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425-1433
25. de Lemos JA, Blazing MA, Wiviott SD et al.; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316
26. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004;292:1365-1367
27. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial JAMA 2001;285:1711-1718
28. Briguori C, Visconti G, Focaccio A et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of ator-vastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54:2157-2163
29. Paraskevas KI, Liapis CD, Hamilton G, et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006;32:286-293